Summary

Regulatory Affairs Market Growth & Trends

The global regulatory affairs market size is expected to reach USD 22.7 billion by 2028 registering a CAGR of 8.4%, according to a new report by Grand View Research, Inc. Rise in drug approvals, label expansions of approved products, along with the presence of Fastrack regulatory pathways are anticipated to facilitate the market growth over the forecast period. Technological advancements in regulatory software and the growing digital transformation in the healthcare industry are also expected to contribute to market growth. In addition, the introduction of Medical Devices Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR) is anticipated to not only change the EU regulatory landscape and increase the stringency of regulations but also increase the number of documents required to be created and maintained by companies.

Furthermore, the changes in the Central Administration for Pharmaceutical Affairs (CAPA) scope in Egypt is anticipated to change the medical device registration process in the country. Such changes in local regulations are anticipated to favor market growth. Furthermore, several regulatory changes related to clinical trials, vaccine development, and product approvals, initiated by the global and local regulatory authorities to expedite patient access to Covid-19 treatments and vaccines, are anticipated to positively affect the market growth. Market players are actively involved in the adoption of advanced technologies, strategic collaborations, and mergers & acquisition, to strengthen their market positions and outperform the competition. For instance, in 2020, ICON acquired MedPass, a medical device CRO, reimbursement, and regulatory consultancy firm. This acquisition is aimed at strengthening the medical device and diagnostic research services portfolio of ICON through the addition of new clinical and regulatory capabilities in Europe.

Regulatory Affairs Market Report Highlights

• Regulatory writing and publishing was the leading service segment in 2019 and is projected to retain its dominant position throughout the forecast years

• This growth is credited to an increase in the outsourcing of selected regulatory functions by major life sciences companies

• The Biologics segment is anticipated to witness the fastest CAGR over the forecast period due to the increasing popularity of personalized medicines and biosimilars

• The oncology indication segment dominated the market in 2019 and will expand further at a steady CAGR from 2020 to 2027

• This growth can be attributed to the rising cancer cases and mortality rate along with the presence of several innovative pipeline products

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Region Wise Market Calculation
1.6.1 Region-wise market: Base estimates
1.6.2 Global market: CAGR calculation
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective - 1: Understanding market dynamics
1.8.2 Objective - 2: Understanding market estimates and forecasts
1.8.3 Objective - 3: Understanding attributes such as strategy framework and competitor categorization
1.8.4 Objective - 4: Understanding the key service and application scopes
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Regulatory Affairs Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market driver analysis
3.2.1.1 Changing regulatory landscape
3.2.1.2 Entry of companies in the global market
3.2.1.3 Life science companies focusing on their core competencies
3.2.1.4 Economic and competitive pressures
3.2.1.5 Demand for faster approval process for breakthrough drugs and devices
3.2.1.6 Growth in emerging areas such as personalized medicine, biosimilars, and orphan drugs
3.2.2 Market restraint analysis
3.2.2.1 Risk associated with data security
3.2.2.2 Monitoring issues and lack of standardization
3.3 Penetration & Growth Prospect Mapping
3.4 Industry Challenges
3.4.1 Managing relationships
3.5 Major Deals and Strategic Alliances Analysis
3.6 Major Deals and Strategic Alliances Analysis (Biotech & ATMPs)
3.7 Regulatory affairs: Market Analysis Tools
3.7.1 SWOT
3.7.2 Industry analysis - Porter’s
3.7.3 PESTEL analysis
Chapter 4 Regulatory affairs Market: Service Segment Analysis
4.1 Regulatory affairs: Service Market Share Analysis, 2020 & 2028
4.2 Regulatory Consulting
4.2.1 Regulatory consulting market, 2016 - 2028 (USD Million)
4.3 Legal Representation
4.3.1 Legal representation market, 2016 - 2028 (USD Million)
4.4 Regulatory Writing and Publishing
4.4.1 Regulatory writing and publishing market, 2016 - 2028 (USD Million)
4.5 Product Registration and Clinical Trial Application
4.5.1 Product registration and clinical trial application market, 2016 - 2028 (USD Million)
4.6 Other Regulatory Services
4.6.1 Other regulatory services market, 2016 - 2028 (USD Million)
Chapter 5 Regulatory Affairs Market: Service Provider Segment Analysis
5.1 Regulatory Affairs: Service Provider Market Share Analysis, 2020 & 2028
5.2 In-house
5.2.1 In-house regulatory affairs market, 2016 - 2028 (USD Million)
5.3 Outsourcing
5.3.1 Outsourcing market, 2016 - 2028 (USD Million)
Chapter 6 Regulatory Affairs Market: Company Size Segment Analysis
6.1 Regulatory Affairs: Company Size Market Share Analysis, 2020 & 2028
6.2 Small Sized
6.2.1 Small companies based regulatory affairs market, 2016 - 2028 (USD Million)
6.3 Medium Sized
6.3.1 Medium-sized companies based regulatory affairs market, 2016 - 2028 (USD Million)
6.4 Large Companies
6.4.1 Large companies based regulatory affairs market, 2016 - 2028 (USD Million)
Chapter 7 Regulatory Affairs Market: Categories Segment Analysis
7.1 Regulatory Affairs: Categories Market Share Analysis, 2020 & 2028
7.2 Drugs
7.2.1 Drugs based regulatory affairs market, 2016 - 2028 (USD Million)
7.2.1.1 Innovator drugs based regulatory affairs market, 2016 - 2028 (USD Million)
7.2.1.1.1 Preclinical drugs based regulatory affairs market, 2016 - 2028 (USD Million)
7.2.1.1.2 Clinical drugs based regulatory affairs market, 2016 - 2028 (USD Million)
7.2.1.1.3 Post market drugs based regulatory affairs market, 2016 - 2028 (USD Million)
7.2.1.2 Generic drugs based regulatory affairs market, 2016 - 2028 (USD Million)
7.2.1.2.1 Preclinical drugs based regulatory affairs market, 2016 - 2028 (USD Million)
7.2.1.2.2 Clinical drugs based regulatory affairs market, 2016 - 2028 (USD Million)
7.2.1.2.3 Post market drugs based regulatory affairs market, 2016 - 2028 (USD Million)
7.3 Biologics
7.3.1 Biologics based regulatory affairs market, 2016 - 2028 (USD Million)
7.3.1.1 Biotech based regulatory affairs market, 2016 - 2028 (USD Million)
7.3.1.1.1 Preclinical drugs based regulatory affairs market, 2016 - 2028 (USD Million)
7.3.1.1.2 Clinical based regulatory affairs market, 2016 - 2028 (USD Million)
7.3.1.1.3 Post market based regulatory affairs market, 2016 - 2028 (USD Million)
7.3.1.2 ATMP based regulatory affairs market, 2016 - 2028 (USD Million)
7.3.1.2.1 Preclinical based regulatory affairs market, 2016 - 2028 (USD Million)
7.3.1.2.2 Clinical based regulatory affairs market, 2016 - 2028 (USD Million)
7.3.1.2.3 Post market based regulatory affairs market, 2016 - 2028 (USD Million)
7.3.1.3 Biosimilar based regulatory affairs market, 2016 - 2028 (USD Million)
7.3.1.3.1 Preclinical based regulatory affairs market, 2016 - 2028 (USD Million)
7.3.1.3.2 Clinical based regulatory affairs market, 2016 - 2028 (USD Million)
7.3.1.3.3 Post market based regulatory affairs market, 2016 - 2028 (USD Million)
7.4 Medical Devices
7.4.1 Medical devices based regulatory affairs market, 2016 - 2028 (USD Million)
7.4.1.1 Diagnostic based regulatory affairs market, 2016 - 2028 (USD Million)
7.4.1.1.1 Preclinical based regulatory affairs market, 2016 - 2028 (USD Million)
7.4.1.1.2 Clinical based regulatory affairs market, 2016 - 2028 (USD Million)
7.4.1.1.3 Post market based regulatory affairs market, 2016 - 2028 (USD Million)
7.4.1.2 Therapeutic based regulatory affairs market, 2016 - 2028 (USD Million)
7.4.1.2.1 Preclinical based regulatory affairs market, 2016 - 2028 (USD Million)
7.4.1.2.2 Clinical based regulatory affairs market, 2016 - 2028 (USD Million)
7.4.1.2.3 Post market based regulatory affairs market, 2016 - 2028 (USD Million)
Chapter 8 Regulatory Affairs Market: Product Stage Segment Analysis
8.1 Regulatory Affairs: Product Stage Market Share Analysis, 2020 & 2028
8.2 Preclinical
8.2.1 Preclinical based regulatory affairs market, 2016 - 2028 (USD Million)
8.3 Clinical
8.3.1 clinical based regulatory affairs market, 2016 - 2028 (USD Million)
8.4 PMA
8.4.1 PMA based regulatory affairs market, 2016 - 2028 (USD Million)
Chapter 9 Regulatory Affairs Market: Indication Segment Analysis
9.1 Regulatory affairs: Indication Market Share Analysis, 2020 & 2028
9.2 Oncology
9.2.1 Oncology based regulatory affairs market, 2016 - 2028 (USD Million)
9.3 Neurology
9.3.1 Neurology based regulatory affairs market, 2016 - 2028 (USD Million)
9.4 Cardiology
9.4.1 cardiology based regulatory affairs market, 2016 - 2028 (USD Million)
9.5 Immunology
9.5.1 Immunology indication based regulatory affairs market, 2016 - 2028 (USD Million)
9.6 Other Indications
9.6.1 Other indication based regulatory affairs market, 2016 - 2028 (USD Million)
Chapter 10 Regulatory Affairs Market: End-use Segment Analysis
10.1 Regulatory affairs: End-use Market Share Analysis, 2020 & 2028
10.2 Medical Device Companies
10.2.1 Medical device companies market, 2016 - 2028 (USD Million)
10.3 Pharmaceutical Companies
10.3.1 Pharmaceutical companies market, 2016 - 2028 (USD Million)
10.4 Biotechnology Companies
10.4.1 Biotechnology companies market, 2016 - 2028 (USD Million)
Chapter 11 Regulatory Affairs Market: Regional Analysis
11.1 Regulatory affairs: Regional Market Share Analysis, 2020 & 2028
11.2 North America
11.2.1 North America regulatory affairs market, 2016 - 2028 (USD Million)
11.2.2 U.S.
11.2.2.1 U.S. Regulatory affairs market, 2016 - 2028 (USD Million)
11.2.3 Canada
11.2.3.1 Canada regulatory affairs market, 2016 - 2028 (USD Million)
11.3 Europe
11.3.1 Europe regulatory affairs market, 2016 - 2028 (USD Million)
11.3.2 U.K.
11.3.2.1 U.K. regulatory affairs market, 2016 - 2028 (USD Million)
11.3.3 Germany
11.3.3.1 Germany regulatory affairs market, 2016 - 2028 (USD Million)
11.3.4 France
11.3.4.1 France regulatory affairs market, 2016 - 2028 (USD Million)
11.3.5 Italy
11.3.5.1 Italy regulatory affairs market, 2016 - 2028 (USD Million)
11.3.6 Spain
11.3.6.1 Spain regulatory affairs market, 2016 - 2028 (USD Million)
11.3.7 Russia
11.3.7.1 Russia regulatory affairs market, 2016 - 2028 (USD Million)
11.3.8 Turkey
11.3.8.1 Turkey regulatory affairs market, 2016 - 2028 (USD Million)
11.3.9 Netherlands
11.3.9.1 Netherlands regulatory affairs market, 2016 - 2028 (USD Million)
11.3.10 Switzerland
11.3.10.1 Switzerland regulatory affairs market, 2016 - 2028 (USD Million)
11.3.11 Sweden
11.3.11.1 Sweden regulatory affairs market, 2016 - 2028 (USD Million)
11.4 Asia Pacific
11.4.1 Asia Pacific regulatory affairs market, 2016 - 2028 (USD Million)
11.4.2 Japan
11.4.2.1 Japan regulatory affairs market, 2016 - 2028 (USD Million)
11.4.3 China
11.4.3.1 China regulatory affairs market, 2016 - 2028 (USD Million)
11.4.4 India
11.4.4.1 India regulatory affairs market, 2016 - 2028 (USD Million)
11.4.5 Australia
11.4.5.1 Australia regulatory affairs market, 2016 - 2028 (USD Million)
11.4.6 South Korea
11.4.6.1 South Korea regulatory affairs market, 2016 - 2028 (USD Million)
11.4.7 Indonesia
11.4.7.1 Indonesia regulatory affairs market, 2016 - 2028 (USD Million)
11.4.8 Malaysia
11.4.8.1 Malaysia regulatory affairs market, 2016 - 2028 (USD Million)
11.4.9 Singapore
11.4.9.1 Singapore regulatory affairs market, 2016 - 2028 (USD Million)
11.4.10 Thailand
11.4.10.1 Thailand regulatory affairs market, 2016 - 2028 (USD Million)
11.4.11 Taiwan
11.4.11.1 Taiwan regulatory affairs market, 2016 - 2028 (USD Million)
11.5 Latin America
11.5.1 Latin America regulatory affairs market, 2016 - 2028 (USD Million)
11.5.2 Brazil
11.5.2.1 Brazil regulatory affairs market, 2016 - 2028 (USD Million)
11.5.3 Mexico
11.5.3.1 Mexico regulatory affairs market, 2016 - 2028 (USD Million)
11.5.4 Argentina
11.5.4.1 Argentina regulatory affairs market, 2016 - 2028 (USD Million)
11.5.5 Colombia
11.5.5.1 Colombia regulatory affairs market, 2016 - 2028 (USD Million)
11.5.6 Chile
11.5.6.1 Chile regulatory affairs market, 2016 - 2028 (USD Million)
11.6 MEA
11.6.1 MEA regulatory affairs market, 2016 - 2028 (USD Million)
11.6.2 South Africa
11.6.2.1 South Africa regulatory affairs market, 2016 - 2028 (USD Million)
11.6.3 Saudi Arabia
11.6.3.1 Saudi Arabia regulatory affairs market, 2016 - 2028 (USD Million)
11.6.4 UAE
11.6.4.1 UAE regulatory affairs market, 2016 - 2028 (USD Million)
11.6.5 Egypt
11.6.5.1 Egypt regulatory affairs market, 2016 - 2028 (USD Million)
11.6.6 Israel
11.6.6.1 Israel regulatory affairs market, 2016 - 2028 (USD Million)
Chapter 12 Company Profiles
12.1 Accell Clinical Research, LLC.
12.1.1 Company overview
12.1.2 Financial performance
12.1.3 Organization structure & team composition
12.1.3.1 Team composition
12.1.4 Service benchmarking
12.1.5 Geographic presence
12.1.6 Strategic initiatives
12.1.7 SWOT
12.2 GenPact Ltd.
12.2.1 Company overview
12.2.2 Financial performance
12.2.3 Organization structure & team composition
12.2.3.1 Team composition
12.2.4 Service benchmarking
12.2.5 Geographic presence
12.2.6 Strategic initiatives
12.2.7 SWOT
12.3 Criterium, Inc.
12.3.1 Company overview
12.3.2 Financial performance
12.3.3 Organization structure & team composition
12.3.3.1 Team composition
12.3.4 Service benchmarking
12.3.5 Geographic presence
12.3.6 SWOT
12.4 PRA Health Sciences
12.4.1 Company overview
12.4.2 Financial performance
12.4.3 Organization structure & team composition
12.4.3.1 Team composition
12.4.4 Service benchmarking
12.4.5 Geographic presence
12.4.6 Strategic initiatives
12.4.7 SWOT
12.5 Promedica International
12.5.1 Company overview
12.5.2 Financial performance
12.5.3 Organization structure & team composition
12.5.3.1 Team composition
12.5.4 Service benchmarking
12.5.5 Geographic presence
12.5.6 SWOT
12.6 WuXi AppTec, Inc.
12.6.1 Company overview
12.6.2 Financial performance
12.6.3 Organization structure & team composition
12.6.3.1 Team composition
12.6.4 Service benchmarking
12.6.5 Geographic presence
12.6.6 Strategic initiatives
12.6.7 SWOT
12.7 Medpace
12.7.1 Company overview
12.7.2 Financial performance
12.7.3 Organization structure & team composition
12.7.3.1 Team composition
12.7.4 Service benchmarking
12.7.5 Geographic presence
12.7.6 SWOT
12.8 Charles River Laboratories International, Inc.
12.8.1 Company overview
12.8.2 Financial performance
12.8.3 Organization structure & team composition
12.8.3.1 Team composition
12.8.4 Service benchmarking
12.8.5 Geographic presence
12.8.6 Strategic initiatives
12.8.7 SWOT
12.9 ICON plc
12.9.1 Company overview
12.9.2 Financial performance
12.9.3 Organization structure & team composition
12.9.3.1 Team composition
12.9.4 Service benchmarking
12.9.5 Geographic presence
12.9.6 Strategic initiatives
12.9.7 SWOT
12.10 Covance
12.10.1 Company overview
12.10.2 Financial performance
12.10.3 Organization structure & team composition
12.10.3.1 Team composition
12.10.4 Service benchmarking
12.10.5 Geographic presence
12.10.6 Strategic initiatives
12.10.7 SWOT
12.11 PAREXEL International Corporation, Inc.
12.11.1 Company overview
12.11.2 Financial performance
12.11.3 Organization structure & team composition
12.11.3.1 Team composition
12.11.4 Service benchmarking
12.11.5 Geographic presence
12.11.6 Strategic initiatives
12.11.7 SWOT
12.12 Freyr
12.12.1 Company overview
12.12.2 Financial performance
12.12.3 Organization structure & team composition
12.12.3.1 Team composition
12.12.4 Service benchmarking
12.12.5 Geographic presence
12.12.6 Strategic initiatives
12.12.7 SWOT


List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviations

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Regulatory affairs market snapshot (2020)
Fig. 9 Regulatory affairs market segmentation
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Number of Trials, By WHO Regions
Fig. 12 Personalized Medicine as a percentage of CDER approved novel molecules.
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 SWOT
Fig. 16 Porter’s five forces analysis
Fig. 17 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 18 Regulatory affairs market service outlook: Segment dashboard
Fig. 19 Regulatory affairs market: service movement analysis
Fig. 20 Regulatory consulting market, 2016 - 2028 (USD Million)
Fig. 21 Legal representation market, 2016 - 2028 (USD Million)
Fig. 22 Regulatory writing and publishing market, 2016 - 2028 (USD Million)
Fig. 23 Product registration and clinical trial application market, 2016 - 2028 (USD Million)
Fig. 24 Other regulatory services market, 2016 - 2028 (USD Million)
Fig. 25 Regulatory affairs market service provider outlook: Segment dashboard
Fig. 26 Regulatory affairs market: service provider movement analysis
Fig. 27 In-house regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 28 Outsourcing regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 29 Regulatory affairs market company size outlook: Segment dashboard
Fig. 30 Regulatory affairs market: Company Size movement analysis
Fig. 31 Small companies based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 32 Medium-sized company based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 33 Large companies based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 34 Regulatory affairs market categories outlook: Segment dashboard
Fig. 35 Regulatory affairs market: Categories movement analysis
Fig. 36 Drugs based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 37 Biologics based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 38 Medical devices based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 39 Regulatory affairs product stage outlook: Segment dashboard
Fig. 40 Regulatory affairs market: Product Stage movement analysis
Fig. 41 Preclinical based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 42 Clinical based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 43 PMA based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 44 Regulatory affairs market indication outlook: Segment dashboard
Fig. 45 Regulatory affairs market: indication movement analysis
Fig. 46 Oncology based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 47 Neurology based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 48 Cardiology based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 49 Immunology indication based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 50 Other indication based regulatory affairs market, 2016 - 2028 (USD Million)
Fig. 51 Regulatory affairs market end-use outlook: Segment dashboard
Fig. 52 Regulatory affairs market: end-use movement analysis
Fig. 53 Medical device companies market, 2016 - 2028 (USD Million)
Fig. 54 Pharmaceutical companies market, 2016 - 2028 (USD Million)
Fig. 55 Biotechnology companies market, 2016 - 2028 (USD Million)
Fig. 56 Regional market: Key takeaways
Fig. 57 Regional outlook, 2020 & 2028
Fig. 58 North America market, 2016 - 2028 (USD Million)
Fig. 59 U.S. market, 2016 - 2028 (USD Million)
Fig. 60 Canada market, 2016 - 2028 (USD Million)
Fig. 61 Europe market, 2016 - 2028 (USD Million)
Fig. 62 U.K. market, 2016 - 2028 (USD Million)
Fig. 63 Germany market, 2016 - 2028 (USD Million)
Fig. 64 France market, 2016 - 2028 (USD Million)
Fig. 65 Italy market, 2016 - 2028 (USD Million)
Fig. 66 Spain market, 2016 - 2028 (USD Million)
Fig. 67 Russia market, 2016 - 2028 (USD Million)
Fig. 68 Turkey market, 2016 - 2028 (USD Million)
Fig. 69 Netherlands market, 2016 - 2028 (USD Million)
Fig. 70 Switzerland market, 2016 - 2028 (USD Million)
Fig. 71 Sweden market, 2016 - 2028 (USD Million)
Fig. 72 Asia Pacific market, 2016 - 2028 (USD Million)
Fig. 73 Japan market, 2016 - 2028 (USD Million)
Fig. 74 China market, 2016 - 2028 (USD Million)
Fig. 75 India market, 2016 - 2028 (USD Million)
Fig. 76 Australia market, 2016 - 2028 (USD Million)
Fig. 77 South Korea market, 2016 - 2028 (USD Million)
Fig. 78 Indonesia market, 2016 - 2028 (USD Million)
Fig. 79 Malaysia market, 2016 - 2028 (USD Million)
Fig. 80 Singapore market, 2016 - 2028 (USD Million)
Fig. 81 Thailand market, 2016 - 2028 (USD Million)
Fig. 82 Taiwan market, 2016 - 2028 (USD Million)
Fig. 83 Latin America market, 2016 - 2028 (USD Million)
Fig. 84 Brazil market, 2016 - 2028 (USD Million)
Fig. 85 Mexico market, 2016 - 2028 (USD Million)
Fig. 86 Argentina market, 2016 - 2028 (USD Million)
Fig. 87 Colombia market, 2016 - 2028 (USD Million)
Fig. 88 Chile market, 2016 - 2028 (USD Million)
Fig. 89 MEA market, 2016 - 2028 (USD Million)
Fig. 90 South Africa market, 2016 - 2028 (USD Million)
Fig. 91 Saudi Arabia market, 2016 - 2028 (USD Million)
Fig. 92 UAE market, 2016 - 2028 (USD Million)
Fig. 93 Egypt market, 2016 - 2028 (USD Million)
Fig. 94 Israel market, 2016 - 2028 (USD Million)
Fig. 95 Organization Structure - Accell Clinical Research, LLC
Fig. 96 SWOT - Accell Clinical Research, LLC
Fig. 97 Organization Structure - Genpact Ltd
Fig. 98 SWOT - Genpact
Fig. 99 Organization Structure - Criterium, Inc.
Fig. 100 SWOT - Criterium, Inc
Fig. 101 Organization Structure - PRA Health Sciences
Fig. 102 SWOT - PRA Health Sciences
Fig. 103 Organization Structure - Promedica International
Fig. 104 SWOT - Promedica International
Fig. 105 Organization Structure -WuXi AppTec
Fig. 106 SWOT - Wuxi AppTec
Fig. 107 Organization Structure - Medpace
Fig. 108 SWOT - Medpace
Fig. 109 Organization Structure - Charles River Laboratories International, Inc.
Fig. 110 SWOT - Charles River Laboratories International, Inc
Fig. 111 Organization Structure - ICON plc
Fig. 112 SWOT - ICON plc
Fig. 113 Organization Structure - Covance, Inc
Fig. 114 SWOT - Covance, Inc
Fig. 115 Organization Structure - PAREXEL International Corporation
Fig. 116 SWOT - PAREXEL International Corporation
Fig. 117 Organization Structure - Freyr
Fig. 118 SWOT - Freyr